Monday April 4, 2016 0 comments
DENVER -- Colorado BioScience Association (CBSA) and Colorado Senator Michael Bennet hosted close to 50 Colorado life science industry leaders to meet FDA Commissioner Dr. Robert Califf as part of a roundtable issues discussion at Aurora’s Anschutz Medical Campus on April 1.
Industry CEOs, academic leaders and researchers presented Dr. Califf with a Colorado viewpoint on top-priority industry issues, including user fees, the regulatory landscape for diagnostics and the FDA’s approach to innovative therapies and technologies.
“It’s a privilege for CBSA to co-host the newly appointed FDA Commissioner, Dr. Califf, with Senator Bennet,” said April Giles, CBSA president and CEO.
“Appointed recently in February, our members appreciate the opportunity to engage with him early in his term. Dr. Califf’s visit validates the significant role Colorado plays in the development of new cures, as well as our Senator’s historical and current leadership in working with his office.”
“Colorado’s growing life science sector is on the leading innovative edge of life-changing research and development,” said Sen. Bennet.
“Today’s discussion is another opportunity to give these entrepreneurs and businesses a voice in Washington and to engage directly with Dr. Califf, the leading voice of the FDA.
“We look forward to continuing to work together to reduce regulatory obstacles, and ensure lifesaving treatments make it to the patients quickly and safely.”
“Today’s conversation with Dr. Califf provided the opportunity to discuss challenging topics—including the regulation of molecular diagnostic tests, and how companies and academic centers can best plan for an unknown regulatory landscape,” said David Brunel, CEO and director of Biodesix.
“I appreciated hearing his perspective on balancing patient access, innovation and safety among different kinds of diagnostics.”
Participants in the roundtable represented the state’s thriving life science ecosystem, with more than 600 companies and institutions that support 122,000 bioscience-related jobs. CBSA members taking part in the discussion highlighted diversity and innovation in CBSA’s 350-strong member base.